Literature DB >> 28515506

Impact of Pharmacy Practice Model Expansion on Pharmacokinetic Services: Optimization of Vancomycin Dosing and Improved Patient Safety.

Zhe Han, Natasha N Pettit, Emily M Landon, Benjamin D Brielmaier.   

Abstract

Background: The impact of pharmacy interventions on optimizing vancomycin therapy has been described, however interventions vary among studies and the most optimal pharmacy practice model (PPM) for pharmacokinetic (PK) services has not been established. Objective: The purpose of this study is to demonstrate the value of 24 hours a day, 7 days a week (24/7) PK services.
Methods: New PK services were implemented in 2 phases with institutional PPM expansion. Phase 1 included universal monitoring by pharmacists with recommendations made to prescribers during business hours. Phase 2 expanded clinical pharmacists' coverage to 24/7 and provided an optional 24/7 pharmacist-managed PK consult service. We compared vancomycin therapeutic trough attainment, dosing, and clinical and safety outcomes between phases 1 and 2 in adult inpatients receiving therapeutic intravenous vancomycin. Results. One hundred and fifty patients were included in each phase. Phase 2 had a greater proportion of vancomycin courses with therapeutic initial trough concentrations (27.5% vs 46.1%; p = 0.002), higher initial trough concentrations (10.9 mcg/mL vs 16.4 mcg/mL; p < 0.001), and optimized initial vancomycin dosing (13.5 mg/kg vs 16.2 mg/kg; p < 0.001). Phase 2 also saw significant reduction in the incidence of vancomycin-associated nephrotoxicity (21.1% vs 11.7%; p = 0.038). Dose optimization and improvement in initial target trough attainment were most notable among intensive care unit (ICU) patients. Conclusions. Our study demonstrated that 24/7 PK services implemented with institutional PPM expansion optimized vancomycin target trough attainment and improved patient safety.

Entities:  

Keywords:  nephrotoxicity; pharmacokinetics; pharmacy practice; vancomycin

Year:  2017        PMID: 28515506      PMCID: PMC5424831          DOI: 10.1310/hpj5204-273

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  17 in total

1.  Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Elizabeth A Neuner; Ed Casabar; Richard Reichley; Peggy S McKinnon
Journal:  Diagn Microbiol Infect Dis       Date:  2010-07       Impact factor: 2.803

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy.

Authors:  Ronald E Polk; Christina Fox; Anne Mahoney; Jim Letcavage; Conan MacDougall
Journal:  Clin Infect Dis       Date:  2007-01-22       Impact factor: 9.079

4.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

5.  Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.

Authors:  Ravina Kullar; Susan L Davis; Thomas N Taylor; Keith S Kaye; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2012-03       Impact factor: 4.705

6.  Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.

Authors:  Ravina Kullar; Steven N Leonard; Susan L Davis; George Delgado; Jason M Pogue; Krista A Wahby; Bonnie Falcione; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2011-05       Impact factor: 4.705

7.  Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.

Authors:  Ravina Kullar; Susan L Davis; Donald P Levine; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

8.  Vancomycin administration: the impact of multidisciplinary interventions.

Authors:  R K Crowley; F Fitzpatrick; D Solanki; S FitzGerald; H Humphreys; E G Smyth
Journal:  J Clin Pathol       Date:  2007-02-09       Impact factor: 3.411

9.  Impact of vancomycin therapeutic drug monitoring on patient care.

Authors:  T E Welty; A K Copa
Journal:  Ann Pharmacother       Date:  1994-12       Impact factor: 3.154

10.  Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring.

Authors:  Maria Swartling; Reetu Gupta; Vicky Dudas; B Joseph Guglielmo
Journal:  Int J Clin Pharm       Date:  2012-02-14
View more
  1 in total

1.  Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors:  Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal:  Eur J Hosp Pharm       Date:  2019-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.